After taking part in a significant event, Avalon GloboCare Corp. (NASD: AVCO) increased 9.22% to $0.52 in after-hours trading on the latest check Thursday.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
What event did AVCO take part in?
The president and chief executive officer of Avalon GloboCare (AVCO), David Jin, M.D., Ph.D., and the chief financial officer, Luisa Ingargiola, gave presentations this week at the 15th annual LD Micro Main Event, which was held from October 25 to 27, 2022, at the Luxe Sunset Boulevard Hotel in Los Angeles, California.
Further from AVCO:
Moreover, Avalon GloboCare recently released an update on its intellectual property portfolio, which includes its QTY protein coding technology. The United States Patent and Trademark Office (USPTO) granted AVCO a Notice of Allowance for their QTY fusion water-soluble receptor protein platform. Dr. Shuguang Zhang of the Massachusetts Institute of Technique (MIT) and I jointly submitted the patent, which includes seven claims pertaining to the technology.
Additionally, Avalon GloboCare filed a fresh patent application with the USPTO for their QTY glucose transporter innovation. Additionally, Dr. Shuguang Zhang of MIT and I jointly submitted this patent application. Numerous tumor types exhibit altered QTY glucose transporters, which might be a crucial target for cancer treatment.
The “QTY Code,” a ground-breaking innovation, may convert challenging-to-work-with transmembrane receptor proteins into water-soluble proteins, opening the door for their prospective use in several therapeutic applications, including medication development.
With the help of artificial intelligence (AI) enhanced QTY Code technology, AVCO’s proprietary AVA-Trap technology transforms receptor molecules into decoy receptors that act like antibodies and can mop up cytokines and chemokines that are overproduced under pathological conditions like COVID-19 and cancer metastasis.
As we think innovative QTY code protein design technology offers enormous potential for biotechnology applications and might lead to major clinical improvements in cellular immunotherapy and immune-oncology, AVCO proceeded to build its IP portfolio. The AI-enhanced protein design QTY Code technology was created in collaboration with Dr. Zhang of MIT and is a cutting-edge platform that generates water-soluble proteins for a variety of medicinal uses, such as the creation of new immunotherapy targets.
How AVCO is proceeding further?
QTY glucose transporters are significant targets for cancer treatment, and Avalon GloboCare (AVCO) just filed a new patent application with the USPTO. Utilizing QTY technology will hasten AVCO’s comprehension of these proteins and the creation of cancer-fighting antibodies.
